NAD+

NAD+ is a redox coenzyme sold as a buffered injectable that users most often take for energy and vitality, with additional reports of increased stamina, disease support, longevity aims, and cognitive benefits. Most users report taking around 50 mg per day (with a span of 1 mg–50 mg), often on a five‑days‑on/two‑days‑off schedule, while clinicians who prescribe it tend to use 100–200 mg daily subcutaneously. While the evidence behind these uses remains limited compared to the talk around them, users occasionally note changes in sleep or dreams, and rarely report injection‑site flushing or histamine‑type reactions; edema, nausea and other effects have not appeared in reports.

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsno dataAnecdotalEfficacyAnecdotalSideEffectsPrice1.91.73.72.35.0

Measured on 5 of 6 axes

Research Evidence

Evidence shape

Human evidence for NAD+ is limited — pilot studies, withdrawn trials, or completed trials without posted results. Off-label / exploratory data exists for 1 additional indication (Cognitive function in aging).

Depthhow much
2 registered trials
2 recruiting / active
Breadthhow many areas
3 indications mapped
2 thin / exploratory · 1 animal-only · 2 single-trial long-tail
Qualityhow rigorous
No completed trials
Breadth and depth18 rows captured
Human
direct clinical signal
2
Animal
translational support
9
In vitro
mechanistic support
7
HighMediumLow

Anecdotal efficacy

NAD+ side effects

Clinical research side effects

Clinical safety table not projected yet.

Anecdotal side effects

Price

Full buying guide →
1
Mai Peptide
--
10000 mg×10
$56.00
$0.01/mg
2
Nurev Peptides
--
1000 mg
$13.99
$0.01/mg
3
High Purity Peptides
Hong Kong
5000 mg×10
$90.00
$0.018/mg
4
Chimera Peptides
CN
5000 mg×10
$109.00
$0.02/mg
5
Saiyan Med
US
5000 mg×10
$95.00
$0.02/mg
6
Uther
unknown
5000 mg×10
$105.00
$0.02/mg

price offers can be sorted by column · 31 out-of-stock offers not shown

1-6 of 306

NAD+ dosing & protocol

How NAD+ is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols
Typical dose
—
0
50 mg
100 mg
150 mg
200 mg
no dose captured for this tier yet
Frequency
single
Route
intranasal

Research trials of NAD+ have not yielded a reliably captured dose; the only dosing detail reported is intranasal administration given as a single administration.

Clinician practice
Doctor & published-protocol guidance
Typical dose
200 mg100 mg – 200 mg
typical
0
50 mg
100 mg
150 mg
200 mg
distribution of 3 reported doses · darker = more
Frequency
daily
Route
subQ

Clinician practice runs 100–200 mg subcutaneously daily, with 200 mg as the typical target dose.

Anecdotal
Community-reported real-world use · n = 42
Typical dose
50 mg1 mg – 50 mg
typical
0
50 mg
100 mg
150 mg
200 mg
distribution of 48 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
mixed
Route
subQ
Cycle
5 days on / 2 days off · 2 reports

Typical NAD+ doses in the community tier are around 50 mg (range 1–50 mg) taken subcutaneously; most users did not state a schedule, while among those who did, weekly (8 reports) and daily (6 reports) were most common, with a minority using three‑times‑weekly (4 reports) or cycling five days on/two days off (2 reports).

42 sources

Related peptides

SS-31MOTS-cHumaninGlutathioneSLU-PP-332